<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Allergy Clin Immunol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Allergy Clin. Immunol</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Allergy and Clinical Immunology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0091-6749</issn>
      <issn pub-type="epub">1097-6825</issn>
      <publisher>
        <publisher-name>Mosby</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25042743</article-id>
      <article-id pub-id-type="pmc">4220006</article-id>
      <article-id pub-id-type="publisher-id">S0091-6749(14)00808-2</article-id>
      <article-id pub-id-type="doi">10.1016/j.jaci.2014.05.044</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Gain-of-function mutations in signal transducer and activator of transcription 1 (<italic>STAT1</italic>): Chronic mucocutaneous candidiasis accompanied by enamel defects and delayed dental shedding</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Frans</surname>
            <given-names>Glynis</given-names>
          </name>
          <degrees>MPharm</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="fn1" ref-type="fn">&#x2217;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moens</surname>
            <given-names>Leen</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="fn1" ref-type="fn">&#x2217;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schaballie</surname>
            <given-names>Heidi</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="aff7" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Van Eyck</surname>
            <given-names>Lien</given-names>
          </name>
          <degrees>MD, MSc</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
          <xref rid="aff7" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Borgers</surname>
            <given-names>Heleen</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wuyts</surname>
            <given-names>Margareta</given-names>
          </name>
          <degrees>BSc</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dillaerts</surname>
            <given-names>Doreen</given-names>
          </name>
          <degrees>MSc</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vermeulen</surname>
            <given-names>Edith</given-names>
          </name>
          <degrees>MPharm</degrees>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dooley</surname>
            <given-names>James</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grimbacher</surname>
            <given-names>Bodo</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff4" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cant</surname>
            <given-names>Andrew</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff5" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Declerck</surname>
            <given-names>Dominique</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff6" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Peumans</surname>
            <given-names>Marleen</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff6" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Renard</surname>
            <given-names>Marleen</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff7" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Boeck</surname>
            <given-names>Kris</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff7" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hoffman</surname>
            <given-names>Ilse</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff7" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fran&#xE7;ois</surname>
            <given-names>Inge</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff7" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liston</surname>
            <given-names>Adrian</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Claessens</surname>
            <given-names>Frank</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff8" ref-type="aff">h</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bossuyt</surname>
            <given-names>Xavier</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meyts</surname>
            <given-names>Isabelle</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>Isabelle.Meyts@uzleuven.be</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="aff7" ref-type="aff">g</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Department of Microbiology and Immunology, Experimental Laboratory Immunology, Katholieke Universiteit Leuven, Leuven, Belgium</aff>
      <aff id="aff2"><label>b</label>Laboratory Genetics of Autoimmunity, Vlaams Instituut Biotechnologie, Leuven, Belgium</aff>
      <aff id="aff3"><label>c</label>Department of Microbiology and Immunology, Laboratory for Clinical Bacteriology and Mycology, Katholieke Universiteit Leuven, Leuven, Belgium</aff>
      <aff id="aff4"><label>d</label>Centre for Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany</aff>
      <aff id="aff5"><label>e</label>Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University and Pediatric Immunology Service, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom</aff>
      <aff id="aff6"><label>f</label>Department of Conservative Dentistry, School for Dentistry, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium</aff>
      <aff id="aff7"><label>g</label>Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium</aff>
      <aff id="aff8"><label>h</label>Department of Cellular and Molecular Medicine, Laboratory of Molecular Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium</aff>
      <author-notes>
        <fn id="fn1">
          <label>&#x2217;</label>
          <p>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <volume>134</volume>
      <issue>5</issue>
      <fpage>1209</fpage>
      <lpage>1213.e6</lpage>
      <permissions>
        <copyright-statement>&#xA9; 2014 The Authors</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
          <license-p> This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p content-type="salutation">To the Editor:</p>
    <p>Heterozygous gain-of-function mutations in signal transducer and activator of transcription 1 <italic>(STAT1)</italic> have recently been identified as a cause of chronic mucocutaneous candidiasis (CMC). Uzel et&#xA0;al<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> described &#x201C;<italic>STAT1</italic> gain-of-function mutations in patients with <italic>FOXP3</italic> wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome.&#x201D; They briefly mentioned the presence of poor enamel in 1 patient and structural and functional gastrointestinal defects in another patient. Here we present a patient with CMC associated with dental anomalies, diaphragmatic hernia, and esophageal dysmotility in whom the phenotype led to a broad differential diagnosis ranging from severe combined immunodeficiency inspired by the neonatal onset of infections to humoral immune&#xA0;deficiency, immune dysregulation&#x2013;polyendocrinopathy&#x2013;enteropathy&#x2013;X-linked syndrome, nuclear factor &#x3BA;B essential modulator <italic>(NEMO)</italic> deficiency, Shwachman-Diamond syndrome, autosomal dominant hyper-IgE syndrome, and, finally, CMC caused by gain-of-function mutation in <italic>STAT1</italic>. We stress the early onset of respiratory tract infections, as well as the dental and gastrointestinal defects, in this patient.</p>
    <p>The patient was born at term small for gestational age (&#x2212;2 SD) as the third son of unrelated parents. He presented with recurrent lower respiratory tract infections from birth, intractable diarrhea, failure to thrive, seborrheic dermatitis, and CMC. Small-bowel biopsy showed villous atrophy interpreted as celiac-like disease, yet diarrhea was unresponsive to a gluten-free diet. Primary dentition showed enamel defects. Recurrent lower respiratory tract infections with <italic>Haemophilus influenzae and Streptococcus pneumoniae</italic> led to the development of bronchiectasis. Partial IgG<sub>2</sub> deficiency (0.34 g/L; normal range, 0.72-3.4 g/L) was found at 3 years of age. Anti-tetanus antibody levels were protective (1.2&#xA0;mg/L; protective level, &gt;1 mg/L), suggesting an intact anti-protein antibody response. Intravenous immunoglobulin (IVIG) substitution was initiated. Diaphragmatic hernia, gastroesophageal reflux disease, and disturbed esophageal motility were demonstrated and led to a Nissen fundoplication.</p>
    <p>At 13 years of age, the patient presented at the immunology clinic with severe growth retardation (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>A</italic>), pubertal delay, bronchiectasis, atonic esophagus with multiple diverticula (<xref rid="fig1" ref-type="fig">Fig&#xA0;1</xref>, <italic>B</italic> and <italic>C</italic>), atrophic duodenal mucosa (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>D</italic>) corresponding to villous blunting or atrophy, joint hyperlaxity, osteopenia with recurrent fractures, delayed dental development with retention of primary teeth necessitating dental extractions (<xref rid="fig1" ref-type="fig">Fig&#xA0;1</xref>, <italic>E</italic> and <italic>F</italic>), severe erosive tooth wear suggestive of enamel hypoplasia (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>E</italic> and <italic>F</italic>), seborrheic dermatitis, aphthous stomatitis, and CMC (see <xref rid="tblE1" ref-type="table">Table E1</xref> in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0010">www.jacionline.org</ext-link>). The autoimmune regulator <italic>(AIRE)</italic> and caspase recruitment domain family, member 9 <italic>(CARD9)</italic>, genes were sequenced, but no mutations were found. After withdrawal of IVIG, antibody response to unconjugated pneumococcal vaccine was tested and showed protective titers for 9 of 14 serotypes tested (see <xref rid="tblE2" ref-type="table">Table E2</xref> in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0015">www.jacionline.org</ext-link>).<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Increased IgG levels (21 g/L; normal range, 5.76-12.65 g/L) and persistent partial IgG<sub>2</sub> deficiency were noted (0.80 g/L; normal range, 1.06-6.10 g/L). An extended autoantibody screening panel was performed, including thyroid-related, adrenal gland&#x2013;related, and anti&#x2013;IFN-&#x3B1; and anti&#x2013;IFN-&#x3C9; antibodies. Only anti&#x2013;salivary gland antibodies were demonstrated (for the entire panel, see the&#xA0;<xref rid="appsec1" ref-type="sec">Methods</xref> section in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0020">www.jacionline.org</ext-link>). Immunophenotyping showed a low percentage of switched memory B cells (1.3%; normal range, 5% to 10%; see <xref rid="tblE3" ref-type="table">Table E3</xref> in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0025">www.jacionline.org</ext-link>). Because withdrawal of IVIG was associated with an increased incidence of pneumonia, treatment was optimized by restarting IVIG and initiating azithromycin (both for antibacterial prophylaxis and its anti-inflammatory actions) and fluconazole prophylaxis, as well as overnight tube feeding. Growth hormone therapy and puberty induction led to a correction of the growth deficit (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>A</italic>). Finally, at the age of 18 years, hypothyroidism was diagnosed almost simultaneously with the initial reports on <italic>STAT1</italic> coiled-coil domain gain-of-function mutations.<xref rid="bib3 bib4" ref-type="bibr"><sup>3,4</sup></xref> A&#xA0;mutation in the DNA-binding domain of <italic>STAT1</italic> was detected (c.1154C&gt;T, p.T385M; <xref rid="fig2" ref-type="fig">Fig 2</xref>, <italic>A</italic>; for information on the analysis, see the <xref rid="appsec2" ref-type="sec">Results</xref> section in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0030">www.jacionline.org</ext-link>). The mutation was not found in the parents or the 2 male siblings of the index patient. As described previously, T385M is a gain-of-function mutation.<xref rid="bib1 bib5 bib6 bib7" ref-type="bibr"><sup>1,5-7</sup></xref> Likewise, we showed increased STAT1 phosphorylation in response to IFN-&#x3B1; and IFN-&#x3B3; in the patient compared with control values (<xref rid="fig2" ref-type="fig">Fig 2</xref>, <italic>B</italic>). Also, the electrophoretic mobility shift assay (EMSA) showed increased gamma-activated sequence (GAS) binding activity on stimulation with IFN-&#x3B3; (<xref rid="fig2" ref-type="fig">Fig 2</xref>, <italic>C</italic>).</p>
    <p>The mechanism that leads to gain of function in the T385M mutation is not entirely clear. Takezaki et&#xA0;al<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> suggested an impaired dephosphorylation of STAT1. However, it is also possible that there is impaired dissociation from the DNA or a problem with the reciprocal association of the DNA-binding domain with the coiled-coil domain. After diagnosis, extended immunophenotyping of PBMCs was performed and showed absence of T<sub>H</sub>17 cells, as described by Liu et&#xA0;al.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref></p>
    <p>The dental anomalies in the patient were impressive. Both primary and permanent teeth showed rapid loss of tooth substance, with severe caries and erosive tooth wear reminiscent&#xA0;of the dental anomalies encountered in patients with Shwachman-Diamond syndrome or Ora1/Stromal interaction molecule 1 deficiency. Moreover, deciduous teeth had to be extracted because of delayed shedding. The latter feature resembles autosomal dominant hyper-IgE syndrome.</p>
    <p>Several hypotheses to explain the dental anomalies were put forward. First, antibiotic and antimycotic therapy and acidic hypercaloric nutrition were blamed. Second, malabsorption of calcium and vitamin D was investigated. Third, in the context of recurrent aphthous stomatitis, a sicca syndrome was suspected. Although salivary flow was low, treatment with oral saliva analogues did not improve the dental condition. There were no biochemical or clinical signs of hypothyroidism until age 18 years in our patient, excluding this as a cause for the delayed shedding of deciduous teeth. Although a role for <italic>STAT1</italic> signaling has been demonstrated in amelogenesis and dentinogenesis in rats, further research is needed to investigate the potential causal relationship between <italic>STAT1</italic> gain-of-function mutation and abnormal dental development.<xref rid="bib8 bib9" ref-type="bibr"><sup>8,9</sup></xref></p>
    <p>Aside from the persistent villous blunting, diaphragmatic hernia and esophageal dysmotility are remarkable gastrointestinal features. On computed tomographic (CT) scanning, as well as endoscopy, the esophagus appeared wide open and atonic, with multiple diverticula present. Thus defects in the development of the upper gastrointestinal tract seem to be a noteworthy feature of this syndrome, as hypothesized by Uzel et&#xA0;al.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Whether the gastrointestinal manifestations are all secondary to CMC or a primary manifestation of disturbed <italic>STAT1</italic> signaling is yet to be determined.<xref rid="bib1 bib6" ref-type="bibr"><sup>1,6</sup></xref></p>
    <p>In conclusion, we report extensive dental anomalies, as well as diaphragmatic hernia and esophageal dysmotility, in a patient&#xA0;with early onset of lower respiratory tract infections in the context of a gain-of-function mutation in the DNA-binding domain&#xA0;of&#xA0;<italic>STAT1</italic>. These features add to the complexity of the phenotype observed in patients with a gain-of-function mutation in <italic>STAT1</italic>.</p>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>Uzel</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Hackett</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dorsey</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Dominant gain-of-function <italic>STAT1</italic> mutations in <italic>FOXP3</italic> wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome</article-title>
          <source>J Allergy Clin Immunol</source>
          <volume>131</volume>
          <year>2013</year>
          <fpage>1611</fpage>
          <lpage>1623</lpage>
          <pub-id pub-id-type="pmid">23534974</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Borgers</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Moens</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Picard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jeurissen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Raes</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sauer</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay</article-title>
          <source>Clin Immunol</source>
          <volume>134</volume>
          <year>2010</year>
          <fpage>198</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="pmid">19914139</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>van de Veerdonck</surname>
              <given-names>F.L.</given-names>
            </name>
            <name>
              <surname>Plantinga</surname>
              <given-names>T.S.</given-names>
            </name>
            <name>
              <surname>Hoischen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Smeekens</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Joosten</surname>
              <given-names>L.A.B.</given-names>
            </name>
            <name>
              <surname>Gilissen</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title><italic>STAT1</italic> mutations in autosomal dominant chronic mucocutaneous candidiasis</article-title>
          <source>N Engl J Med</source>
          <volume>365</volume>
          <year>2011</year>
          <fpage>54</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">21714643</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Kreins</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cypowyj</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Abhynkar</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Gain-of-function human <italic>STAT1</italic> mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis</article-title>
          <source>J Exp Med</source>
          <volume>208</volume>
          <year>2011</year>
          <fpage>1635</fpage>
          <lpage>1648</lpage>
          <pub-id pub-id-type="pmid">21727188</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Takezaki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Chronic&#xA0;mucocutaneous candidiasis caused by a gain of function mutation in the STAT1 DNA binding domain</article-title>
          <source>J Immunol</source>
          <volume>189</volume>
          <year>2012</year>
          <fpage>1521</fpage>
          <lpage>1526</lpage>
          <pub-id pub-id-type="pmid">22730530</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Soltesz</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Toth</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Shabahova</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Bondarenko</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cypowyj</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>New&#xA0;and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe</article-title>
          <source>J Med Genet</source>
          <volume>50</volume>
          <year>2013</year>
          <fpage>567</fpage>
          <lpage>578</lpage>
          <pub-id pub-id-type="pmid">23709754</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal" id="sref7">
          <person-group person-group-type="author">
            <name>
              <surname>Sampaio</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Pechacek</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bax</surname>
              <given-names>H.I.</given-names>
            </name>
            <name>
              <surname>Dias</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Paulson</surname>
              <given-names>M.L.</given-names>
            </name>
          </person-group>
          <article-title>Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis</article-title>
          <source>J Allergy Clin Immunol</source>
          <volume>131</volume>
          <year>2013</year>
          <fpage>1624</fpage>
          <lpage>1634</lpage>
          <pub-id pub-id-type="pmid">23541320</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Otsuji</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Tanase</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bawden</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>The immunohistochemical localization of the interferon-gamma and granulocyte colony stimulating factor receptors during early amelogenesis in rat molars</article-title>
          <source>Arch Oral Biol</source>
          <volume>44</volume>
          <year>1999</year>
          <fpage>173</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="pmid">10206335</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>Tanase</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bawden</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>The immunohistochemical localization of signal-transduction pathway components Jak1, Jak2, Jak3, Tyk2 and <italic>STAT1</italic> during early enamel and dentine formation in rat molars</article-title>
          <source>Arch Oral Biol</source>
          <volume>41</volume>
          <year>1996</year>
          <fpage>925</fpage>
          <lpage>940</lpage>
          <pub-id pub-id-type="pmid">9031700</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ref-list>
      <title>References</title>
      <ref id="bibE1">
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Oftedal</surname>
              <given-names>B.E.</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Bratland</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>K&#xE4;mpe</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Perheentupa</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Myhre</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>Radioimmunoassays for autoantibodies against interferon omega: its use in the diagnosis of autoimmune polyendocrine syndrome type I</article-title>
          <source>Clin Immunol</source>
          <volume>129</volume>
          <year>2008</year>
          <fpage>163</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="pmid">18708298</pub-id>
        </element-citation>
      </ref>
      <ref id="bibE2">
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Denayer</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Helsen</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Thorrez</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Haelens</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Claessens</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>The rules of DNA recognition by the androgen receptor</article-title>
          <source>Mol Endocrinol</source>
          <volume>24</volume>
          <year>2010</year>
          <fpage>898</fpage>
          <lpage>913</lpage>
          <pub-id pub-id-type="pmid">20304998</pub-id>
        </element-citation>
      </ref>
      <ref id="bibE3">
        <element-citation publication-type="journal" id="sref12">
          <person-group person-group-type="author">
            <name>
              <surname>Chapgier</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Boisson-Dupuis</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jouanguy</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Vogt</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Feinberg</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Prochnicka-Chalufour</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease</article-title>
          <source>PLoS Genet</source>
          <volume>2</volume>
          <year>2006</year>
          <fpage>e131</fpage>
          <pub-id pub-id-type="pmid">16934001</pub-id>
        </element-citation>
      </ref>
      <ref id="bibE4">
        <mixed-citation publication-type="other" id="oref1">Rasband WS. ImageJ. Bethesda: US National Institutes of Health. Available at: <ext-link ext-link-type="uri" xlink:href="http://imagej.nih.gov/ij/" id="intref0040">imagej.nih.gov/ij/</ext-link>.</mixed-citation>
      </ref>
      <ref id="bibE5">
        <element-citation publication-type="journal" id="sref13">
          <person-group person-group-type="author">
            <name>
              <surname>Borgers</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Moens</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Picard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jeurissen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Raes</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sauer</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay</article-title>
          <source>Clin Immunol</source>
          <volume>134</volume>
          <year>2010</year>
          <fpage>198</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="pmid">19914139</pub-id>
        </element-citation>
      </ref>
      <ref id="bibE6">
        <element-citation publication-type="journal" id="sref14">
          <person-group person-group-type="author">
            <name>
              <surname>Danso-Abeam</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Dooley</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Staats</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Van Eyck</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Van Brussel</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Olmsted syndrome: exploration of the immunological phenotype</article-title>
          <source>Orphanet J&#xA0;Rare Dis</source>
          <volume>8</volume>
          <year>2013</year>
          <fpage>79</fpage>
          <pub-id pub-id-type="pmid">23692804</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="appsec1">
      <title>Methods</title>
      <sec id="appsec1.1">
        <title>Measurement of salivary flow rate</title>
        <p>Salivary flow rate was measured through standardized collection of nonstimulated (resting) and stimulated (paraffin-chewing) saliva over a time span of 5 minutes.</p>
      </sec>
      <sec id="appsec1.2">
        <title>Autoantibody analysis</title>
        <p>The autoantibody panel analyzed consisted of anti&#x2013;nuclear antigen, anti&#x2013;neutrophil cytoplasmic, anti-thyroglobulin, anti&#x2013;thyroid peroxidase, anti&#x2013;thyrotropin receptor, anti&#x2013;parietal cell, anti&#x2013;intrinsic factor, anti&#x2013;smooth muscle, anti-mitochondrial, anti-pancreatic, anti-insulin, anti-GAD65kDA, anti&#x2013;liver kidney microsome, anti&#x2013;proteinase 3, anti-myeloperoxidase, and anti&#x2013;IFN-&#x3B1; and anti&#x2013;IFN-&#x3C9; antibodies. The latter analysis was performed by Anette S. Boe Wolff and Husebye Eystein, Bergen, Norway, because of the diagnostic value in patients with autoimmune polyendocrine syndrome type 1.<xref rid="bibE1" ref-type="bibr"><sup>E1</sup></xref></p>
      </sec>
      <sec id="appsec1.3">
        <title>Genetic analysis</title>
        <p>Genomic DNA was extracted from EDTA blood by using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). The UM13F/R-tagged primers (Life Technologies, Ghent, Belgium) used for genotyping <italic>STAT1</italic> hotspots (gene ID 6772, ENSG00000115415) were designed with Oligo7 software (OLIGO Primer Analysis Software Version 7, assembled in 2009 by Wojciech Rychlik, Molecular Biology Insights, Cascade, Colo; <ext-link ext-link-type="uri" xlink:href="http://www.oligo.net/" id="intref0035">http://www.oligo.net/</ext-link>) and were as follows, respectively: AGTACAATAAAGTAAACATTCTGC (F1) and CTAAATCTGATTCTCCCACTT (R1); AGTCACACCCTGAAGAAAACGATG (F2) and CTGCAAAATTTTTCTTCCCAA (R2); AGTCTAAAGTCTTTGGAAGTTGCT (F3) and CTGGCCTGGGTTATCAAGGAA (R3); AGTTCTTCTTTATATATTTACTGG (F4) and GGTGGCTATAATTTTTCCTCT (R4); AGTTGAGAATGAAATGATATTTGC (F5) and GTGTTTATGTGGTTAGCCAGT (R5); AGTCTTCTGGACTGTTTCTCATAG (F6) and ATCATCTGAATTAACGGTAAA (R6); AGTCCTCAACCTTAATGGAAATGC (F7) and CTCAAAAGCACCCTATATAAC (R7); AGTAAACGTTAATAGGGAATTGGC (F8) and CCTAGGGAGGCAAACTTCCAC (R8); and AGTCTCTTATAATTTTGTTAAAGC (F9) and CCTACCAGGTGCCGAAATTCA (R9).</p>
        <p>PCR samples were prepared by using AccuPrime SuperMix II (Life Technologies, Belgium) and run on a Veriti Thermal Cycler (Applied Biosystems, Foster City, Calif). Purified PCR products (PCR purification kit, Qiagen) were sequenced by BaseClear (Leiden, The Netherlands) and analyzed with Chromas 2.33 Software.</p>
      </sec>
      <sec id="appsec1.4">
        <title>Analysis of phosphorylated STAT1 by using flow cytometry</title>
        <p>Peripheral blood was left unstimulated or stimulated with IFN-&#x3B3; (2000&#xA0;IU/mL) or IFN-&#x3B1; (10*5 IU/mL) for 15 minutes. Cells were lysed (Lyse/Fix Buffer; BD Phosflow; BD Biosciences, San Jose, Calif) for 10&#xA0;minutes at 37&#xB0;C and washed with 1 mL of Stain Buffer (BD PharMingen, San Jose, Calif). Thereafter, the cells were permeabilized (Perm Buffer III [BD Phosflow]) for 30 minutes on ice. Cells were washed, resuspended in 100 &#x3BC;L of stain buffer, and stained with phycoerythrin-labeled antibody specific for phosphorylated STAT1 (pY701; BD Biosciences). Phosphorylated STAT1 was evaluated in the lymphocyte gate. Analysis was performed on a FACSCanto II instrument (BD Biosciences).</p>
      </sec>
      <sec id="appsec1.5">
        <title>Western blot analysis</title>
        <p>Nuclear extracts of patient- or control subject&#x2013;derived fibroblast (obtained&#xA0;from skin biopsy) cultures (unstimulated or stimulated with IFN-&#x3B1; [100 U/mL] or IFN-&#x3B3; [100 U/mL] for 1 hour) were prepared, as described previously.<xref rid="bibE2" ref-type="bibr"><sup>E2</sup></xref> Nuclear protein lysates (5 &#x3BC;g per sample) were subjected to SDS-PAGE separation on 4-12% Bis-Tris Plus gels (Life Technologies, Carlsbad, Calif), and proteins were transferred to a polyvinylidene difluoride membrane (GE Healthcare, Buckinghamshire, United Kingdom) and immunoblotted with primary antibodies (STAT1 p84/p91 [M-22, sc-592; Santa Cruz Biotechnology, Dallas, Tex], phospho-STAT1 [Tyr701, sc-7988, Santa Cruz Biotechnology], and loading control heterogeneous nuclear ribonucleoprotein I [3H7, sc-73391, Santa Cruz Biotechnology]) and detected with horseradish peroxidase&#x2013;conjugated secondary antibody (sc-2317 and sc-2005, Santa Cruz Biotechnology). All Western blot images were captured and quantified with a ChemiDoc MP imager and Image Lab software (Bio-Rad Laboratories, Hercules, Calif) after adding Pierce ECL Western blotting substrate (Thermo Scientific, Waltham, Mass). Relative phosphorylated STAT1 expression is normalized to the respective value for heterogeneous nuclear ribonucleoprotein I expression, and the results are described as fold increases relative to the baseline level in the unstimulated condition of the sample.</p>
      </sec>
      <sec id="appsec1.6">
        <title>EMSA</title>
        <p>EMSA was performed, as described previously.<xref rid="bibE2" ref-type="bibr"><sup>E2</sup></xref> Probe (20,000 cpm) was added to 1 &#x3BC;g of nuclear extract in 50 ng/&#x3BC;L dI-dC, 1 mmol/L dithiothreitol, and 0.05% Triton. EMSA results with nonstimulated extracts or extracts stimulated with IFN-&#x3B1; or IFN-&#x3B3; were compared. The GAS probe (5&#x2032;-TCGAACATTTCCCGTAAATCATG-3&#x2032;, Chapgier et&#xA0;al<xref rid="bibE3" ref-type="bibr"><sup>E3</sup></xref>) was labeled by a fill-in reaction with the Klenow fragment. EMSA results with nonstimulated extracts&#xA0;(dimethyl sulfoxide vehicle treated) or extracts stimulated with IFN-&#x3B1; (100 U/mL) or IFN-&#x3B3; (100 U/mL) were compared in 2 control subjects (C1 and C2), the T385M patient (P1), and a patient with CMC with a K388E mutation in the DNA-binding domain (P2). Intensities of GAS-binding activity were determined by using ImageJ software.<xref rid="bibE4" ref-type="bibr"><sup>E4</sup></xref></p>
      </sec>
      <sec id="appsec1.7">
        <title>Stimulation of PBMCs and measurement of cytokines</title>
        <p>PBMCs were prepared from heparinized peripheral blood by means of centrifugation through Ficoll (Lymphoprep, Axis-shield, Oslo, Norway). PBMCs were seeded at 2 &#xD7; 10<sup>6</sup> cells/mL in a 96-well culture plate and stimulated with heat-inactivated <italic>Candida albicans</italic> (2.64 &#xD7; 10<sup>3</sup> colony-forming units [CFU]/mL), <italic>Staphylococcus aureus</italic> (10<sup>8</sup> CFU/mL; InvivoGen, San Diego, Calif), or PHA (0.18 mg/mL). IFN-&#x3B3; levels were measured in the supernatant after 48 hours of incubation at 37&#xB0;C (5% CO<sub>2</sub>) and IL-17A levels were measured after 120 hours of incubation at 37&#xB0;C (5% CO<sub>2</sub>) by means of ELISA (commercial kits by BD Biosciences and BioLegend [San Diego, Calif], respectively). For the production of heat-inactivated <italic>C albicans</italic>, reference strain ATCC 90028 was used. This strain was cultured on Sabouraud agar slants at 37&#xB0;C. Yeast colonies were resuspended in RPMI agar and checked microscopically for the absence of hyphae. This yeast stock suspension was adjusted to a concentration of 0.4&#xA0;&#xD7; 10<sup>7</sup> CFU/mL. <italic>C albicans</italic> was subsequently heat killed by exposure to a 60&#xB0;C water bath for 1.5 hours. The sterility of this suspension was checked by subculturing 50 &#x3BC;L of the yeast suspension on blood agar at 37&#xB0;C.</p>
      </sec>
      <sec id="appsec1.8">
        <title>Immune response to Pneumovax</title>
        <p>Antibodies to pneumococcal polysaccharides were measured by using a mulitplex bead assay.<xref rid="bibE5" ref-type="bibr"><sup>E5</sup></xref></p>
      </sec>
      <sec id="appsec1.9">
        <title>Extended peripheral blood immunophenotying panel</title>
        <p>PBMC immunophenotyping was performed, as described previously.<xref rid="bibE6" ref-type="bibr"><sup>E6</sup></xref> In brief, PBMCs were isolated from heparinized blood of the patient and 10 age-matched control subjects (mean age, 22.7 years [SD, 4.62 years]) by using lymphocyte separation medium (MP Biomedicals, Santa Ana, Calif) and frozen in 10% dimethyl sulfoxide (Sigma, St Louis, Mo). Thawed cells were stained with eBioscience (San Diego, Calif) antibodies against CD3 (SK7), CD4 (RPA-T4), and IL-17 (eBio64DEC17). For cytokine staining, T&#xA0;cells were stimulated <italic>ex&#xA0;vivo</italic> for 5 hours in 50 ng/mL phorbol 12-myristate 13-acetate (Sigma) and 500 ng/mL ionomycin (Sigma) in the presence of GolgiStop (BD Biosciences) before staining. Before intracellular staining, cells were first surface stained as described, fixed, and permeabilized with Cytofix/Cytoperm (BD) for IL-17 stainings. Data were acquired on BD FACSCanto II and analyzed with FlowJo software (Tree Star, Ashland, Ore).</p>
      </sec>
    </sec>
    <sec id="appsec2">
      <title>Results</title>
      <sec id="appsec2.1">
        <title>Salivary flow rate</title>
        <p>The nonstimulated salivary flow rate in the index patient was&#xA0;less than 0.2 mL/5 minutes; the stimulated flow rate was 3.1&#xA0;mL/5 minutes.</p>
      </sec>
      <sec id="appsec2.2">
        <title>T385M is a gain-of-function mutation</title>
        <p>On stimulation with IFN-&#x3B1; and IFN-&#x3B3;, higher levels of STAT1 phosphorylation were observed by means of flow cytometry in the patient compared with those seen in a control subject (<xref rid="fig2" ref-type="fig">Fig 2</xref>, <italic>B</italic>). Next, we studied STAT1-binding activity to a GAS oligonucleotide probe by using EMSA. First, we studied the STAT1 phophorylation in skin-derived fibroblasts using Western blotting. We demonstrated an increased expression of total STAT1 in both the T385M patient (P1) and a second patient with CMC caused by a novel mutation in the DNA-binding domain (K388E; P2), although less pronounced than that in P2, compared with that seen in 2 healthy control subjects. Expression of phosphorylated STAT1 was increased in the nuclear extracts of both the T385M and K388E patients, although again less pronounced in the latter, after stimulation for 1 hour with IFN-&#x3B3;. The phosphorylation of STAT1 in P1 and P2 was 7 and 2.7 times more intense than in C2 (<xref rid="fig2" ref-type="fig">Fig 2</xref>, <italic>C</italic>). On stimulation with IFN-&#x3B3;, an increase in GAS-binding activity was detected in the T385M patient (P1; <xref rid="fig2" ref-type="fig">Fig 2</xref>, <italic>C</italic>), as well as in the K388E patient (P2). The intensity of STAT1-binding activity to a GAS probe was quantified to be 16.8 and 2.4 times upregulated in P1 and P2, respectively, compared with the intensity in C2, which was set to 1 in ImageJ software.</p>
      </sec>
      <sec id="appsec2.3">
        <title>PBMCs of the patient do not induce IL-17</title>
        <p>PBMCs of the patient do not induce IL-17 after stimulation with heat-inactivated <italic>C albicans</italic>, <italic>S aureus</italic>, or PHA. IL-17 in the supernatant was undetectable after stimulation with the above-mentioned stimuli (<xref rid="dfig1" ref-type="fig">Fig E1</xref>, <italic>A</italic>). IFN-&#x3B3; production after stimulation with PHA, heat-inactivated <italic>C albicans</italic>, and <italic>S aureus</italic> in the patient and a control subject are also shown (<xref rid="dfig1" ref-type="fig">Fig E1</xref>, <italic>B</italic>).</p>
      </sec>
      <sec id="appsec2.4">
        <title>Extended immunophenotyping at age 20 years</title>
        <p>Using extended immunophenotyping, we showed that the patient has no detectable T<sub>H</sub>17 cells.<fig id="dfig1" position="anchor"><label>Fig E1</label><caption><p><bold>A,</bold> IL-17 production in PBMCs of the T385M patient and a healthy control subject after stimulation with PHA, heat-inactivated <italic>C albicans</italic>, or heat-inactivated <italic>S aureus</italic>. Results shown are derived from one representative experiment of 4 independent experiments. <bold>B,</bold> IFN-&#x3B3; production in PBMCs of the T385M patient and a healthy control subject after stimulation with PHA, heat-inactivated <italic>C albicans</italic>, or heat-inactivated <italic>S aureus</italic>. Results shown are derived from one representative experiment of 4 independent experiments. <italic>HKCA</italic>, Heat-killed <italic>C albicans</italic>; <italic>HKSA</italic>, heat-killed <italic>S aureus</italic>.</p></caption><graphic xlink:href="fx1"/></fig><table-wrap id="tblE1" position="anchor"><label>Table E1</label><caption><p>Clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Present age</th><th>20 y</th></tr></thead><tbody><tr><td>Ethnicity</td><td>White</td></tr><tr><td>Initial presentation</td><td>At birth</td></tr><tr><td>CMC</td><td>Oral, esophageal, skin</td></tr><tr><td>Teeth</td><td>Retained primary dentition, severe caries and erosive tooth wear</td></tr><tr><td>Skin</td><td>Severe seborrheic dermatitis</td></tr><tr><td>Pulmonary infections</td><td>From birth</td></tr><tr><td/><td><italic>Haemophilus influenzae</italic>, <italic>Streptococcus pneumoniae</italic>, <italic>Pseudomonas aeruginosa</italic></td></tr><tr><td/><td><italic>Aspergillus fumigatus</italic></td></tr><tr><td/><td>Bronchiectasis at age 3 y, chronic obstructive pulmonary disease</td></tr><tr><td>Other infections</td><td>Molluscum contagiosum, <italic>Pseudomonas</italic> folliculitis, herpes zoster (2&#xD7;)</td></tr><tr><td>Cardiovascular</td><td>&#x2212;</td></tr><tr><td>Central nervous system</td><td>&#x2212;</td></tr><tr><td>Endocrine</td><td>At birth: small for gestational age</td></tr><tr><td/><td>Growth retardation</td></tr><tr><td/><td>Delayed puberty</td></tr><tr><td/><td>Hypothyroidism (antibodies &#x2212;) at age 18 y</td></tr><tr><td>Gastrointestinal</td><td>Oral aphthous ulcers, recurrent ulcerative gastritis, esophagitis</td></tr><tr><td/><td>Duodenal atrophic mucosa, villous blunting</td></tr><tr><td/><td>Diaphragmatic hernia</td></tr><tr><td>Bone</td><td>Osteopenia, multiple fractures</td></tr><tr><td>Other</td><td>Cystic fibrosis and primary ciliary dyskinesia were excluded.</td></tr></tbody></table></table-wrap><table-wrap id="tblE2" position="anchor"><label>Table E2</label><caption><p>Specific anti-pneumococcal antibody concentrations (in milligrams per miter) in the patient 3 weeks after vaccination with unconjugated pneumococcal vaccine</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>PS1</th><th>PS3</th><th>PS4</th><th>PS8</th><th>PS9N</th><th>PS12F</th><th>PS14</th><th>PS19F</th><th>PS23F</th><th>PS6B</th><th>PS7F</th><th>PS18C</th><th>PS19A</th><th>PS9V</th></tr></thead><tbody><tr><td>Patient</td><td align="char">0.28</td><td align="char">0.37</td><td align="char">2.33</td><td align="char">0.20</td><td align="char">1.31</td><td align="char">0.38</td><td align="char">6.37</td><td align="char">2.71</td><td align="char">5.44</td><td align="char">4.11</td><td align="char">1.35</td><td align="char">2.52</td><td align="char">0.91</td><td align="char">2.81</td></tr><tr><td>Cutoff</td><td align="char">0.53</td><td align="char">0.64</td><td align="char">0.49</td><td align="char">1.02</td><td align="char">0.63</td><td align="char">0.46</td><td align="char">0.57</td><td align="char">0.74</td><td align="char">0.24</td><td align="char">0.80</td><td align="char">1.45</td><td align="char">0.34</td><td align="char">0.96</td><td align="char">0.69</td></tr></tbody></table><table-wrap-foot><fn><p>The postvaccination serotype-specific fifth percentile <italic>(Cutoff)</italic> values obtained in 75 healthy subjects are provided as well. <italic>PS</italic>, Pneumococcal serotype.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tblE3" position="anchor"><label>Table E3</label><caption><p>Immunologic characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Age 1 y</th><th>Age 3 y</th><th>Age 13 y</th><th>Age 20 y<xref rid="tblE3fnlowast" ref-type="table-fn">&#x2217;</xref></th></tr></thead><tbody><tr><td>Lymphocyte subsets</td><td/><td/><td/><td/></tr><tr><td>&#xA0;CD19<sup>+</sup> B cells</td><td/><td/><td>622/&#x3BC;L (82-476/&#x3BC;L)</td><td/></tr><tr><td>&#xA0;Naive CD19<sup>+</sup>CD27<sup>&#x2212;</sup> cells</td><td/><td/><td>94% of CD19<sup>+</sup> (60-80)</td><td/></tr><tr><td>&#xA0;IgM memory CD27<sup>+</sup>IgM<sup>+</sup> cells</td><td/><td/><td>1.3% of CD19<sup>+</sup> (1-5)</td><td/></tr><tr><td>&#xA0;Switched memory CD27<sup>+</sup>IgM<sup>&#x2212;</sup> cells</td><td/><td/><td>1% of CD19<sup>+</sup> (&gt;5)</td><td/></tr><tr><td>&#xA0;CD3<sup>+</sup>CD4<sup>+</sup>T cells</td><td/><td/><td>886/&#x3BC;L (455-1885 &#x3BC;L)</td><td/></tr><tr><td>&#xA0;CD3<sup>+</sup>CD8<sup>+</sup> T cells</td><td/><td/><td>459/&#x3BC;L (219-1124/&#x3BC;L)</td><td/></tr><tr><td>&#xA0;Naive CD4<sup>+</sup> cells</td><td/><td/><td>75% of CD3 (30% to 65%)</td><td/></tr><tr><td>&#xA0;T<sub>H</sub>17 cells</td><td/><td/><td/><td>T<sub>H</sub>17 cells 0% (0.03-0.67)</td></tr><tr><td colspan="2">Lymphocyte proliferation</td><td/><td/><td/></tr><tr><td>&#xA0;PHA</td><td>Normal</td><td/><td>Normal</td><td/></tr><tr><td>&#xA0;Concanavalin A</td><td>Normal</td><td/><td>Normal</td><td/></tr><tr><td>&#xA0;Tetanus</td><td>Normal</td><td/><td>Normal</td><td/></tr><tr><td>&#xA0;Candida</td><td>Normal</td><td/><td>Normal</td><td/></tr><tr><td colspan="5">Immunoglobulin levels (g/L)</td></tr><tr><td>&#xA0;IgG</td><td/><td align="char">16.7 (4.8-11.3)</td><td align="char">21.4 (5.8-12.7)</td><td align="char">22.8 (7.51-15.60)</td></tr><tr><td>&#xA0;IgG<sub>2</sub></td><td/><td align="char">0.34 (0.72-3.40)</td><td align="char">0.80 (1.06-6.10)</td><td align="char">1.8 (1.5-6.4)</td></tr><tr><td>&#xA0;IgA</td><td/><td align="char">0.78 (0.35-1.9)</td><td align="char">1 (0.81-2.32)</td><td align="char">0.28 (0.82-4.53)</td></tr><tr><td>&#xA0;IgM</td><td/><td align="char">1.11 (0.34-1.34)</td><td align="char">1.2 (0.30-1.59)</td><td align="char">0.72 (0.43-3.04)</td></tr></tbody></table><table-wrap-foot><fn><p>Normal values are shown in parentheses.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblE3fnlowast"><label>&#x2217;</label><p>During IVIG treatment.</p></fn></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <ack id="ack0010">
      <p>We thank the patient and his family for their confidence. We also thank the entire paramedical and medical staff of UZ Leuven, as well as Dr De Koster, for their dedicated care. Finally, we thank Mrs R. Bollen and H. De Bruyn for excellent technical assistance.</p>
    </ack>
    <fn-group>
      <fn id="d32e107">
        <p>Supported by a research grant from the <funding-source id="gs1">Fonds Wetenschappelijk Onderzoek - Vlaanderen</funding-source> and by a research grant from the <funding-source id="gs2">Research Council of the Catholic University of Leuven</funding-source>. X.B. is a senior clinical investigator of the Fonds Wetenschappelijk Onderzoek - Vlaanderen. I.M. is funded by a K.O.F. grant of the <funding-source id="gs4">Katholieke Universiteit Leuven</funding-source> and by a grant of the <funding-source id="gs5">Jeffrey Modell Foundation</funding-source>. L.M., H. S.,&#xA0;and L.V.E. are funded by a research grant of the <funding-source id="gs6">Fonds Wetenschappelijk Onderzoek - Vlaanderen</funding-source>. X.B., I.M., A.L., and G.F. are funded by a G.O.A. grant of the <funding-source id="gs7">Katholieke Universiteit Leuven</funding-source>. A.L. is funded by a <funding-source id="gs8">European Research Council</funding-source> grant (IMMUNO).</p>
      </fn>
      <fn id="d32e132">
        <p>Disclosure of potential conflict of interest: G. Frans has received research support from the <funding-source id="gs9">Catholic University of Leuven</funding-source>. L. Moens, H. Schaballie, and E. Vermeulen have received research support from <funding-source id="gs10">Fonds Wetenschappelijk Onderzoek - Vlaanderen</funding-source>. L. Van Eyck has received research support from <funding-source id="gs11">Fonds Wetenschappelijk Onderzoek - Vlaanderen</funding-source> and is employed by University Hospital Leuven. J. Dooley and A. Listons have received research support from the <funding-source id="gs12">European Research Council</funding-source>. B. Grimbacher has received research support from the <funding-source id="gs13">German Federal Ministry of Education and Research</funding-source>, the <funding-source id="gs14">European Union</funding-source>, and <funding-source id="gs15">Helmholtz</funding-source>; is employed by University College London and University Medical Center Freiburg; and has received payment for lectures from CSL, Baxter, and Biotest. M. Renard is employed by University Hospital Leuven. K. De Boeck serves on boards for Vertex, Aptalis, and Pharmaxix and has consultant arrangements with Ablynx, Galapagos, Gilead, and PTC. I. Meyts has received financial support from the <funding-source id="gs16">Jeffrey Modell Foundation</funding-source>. The rest of the authors declare that they have no relevant conflicts of interest.</p>
      </fn>
    </fn-group>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Fig 1</label>
      <caption>
        <p>Clinical characteristics. <bold>A,</bold> Growth charts showing severe growth retardation that only picks up after growth hormone therapy and puberty induction with tube feeding overnight. <italic>Arrows</italic> indicate onset of tube feeding and growth hormone therapy, respectively. <bold>B,</bold> Computed tomography showing an atonic esophagus <italic>(arrow)</italic> with air containing paraesophageal diverticula. <bold>C,</bold> Computed tomography of the chest showing multiple saccular bronchiectases and bronchial wall thickening. <bold>D,</bold> Atrophy in the duodenum, as&#xA0;seen on endoscopy. <bold>E</bold> and <bold>F,</bold> Severe erosive tooth wear, caries, and retained primary teeth.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Fig 2</label>
      <caption>
        <p>The mutant T385M <italic>STAT1</italic> allele is a gain-of-phosphorylation and gain-of-function mutation. <bold>A,</bold>&#xA0;Direct sequence analysis of exon 14 of <italic>STAT1</italic> (forward sequence) in a control subject and the patient with a c.1153C&gt;T resulting in p.T385M. <bold>B,</bold> Intracellular staining of phosphorylated tyrosine 701 STAT1 <italic>(STAT1p)</italic> in lymphocytes after stimulation with IFN-&#x3B3; (2000 IU/mL, <italic>left panel</italic>) or IFN-&#x3B1; (10<sup>5</sup> IU/mL, <italic>right panel</italic>) for 15 minutes. STAT1 and STATp are shown in a control subject (red) and in the T385M patient <italic>(blue)</italic>. Unstimulated conditions are represented as <italic>dashed lines</italic>. Results shown are representative of 2 independent experiments. <italic>MFI</italic>, Mean fluorescence intensity. <bold>C,</bold> Evaluation of STAT1, STAT1 phosphorylation, and STAT1p GAS DNA-binding capacity. Fibroblasts derived from wild-type (WT)/WT control subjects (C1 and C2), p.T385M/WT (patient P1), and p.K388E/WT (patient P2) were stimulated with 100 U/mL IFN-&#x3B1; <italic>(&#x3B1;)</italic> or 100 U/mL IFN-&#x3B3; <italic>(&#x3A5;)</italic> or left unstimulated <italic>(&#x2212;)</italic> for 60 minutes. <italic>a</italic>, Western blotting was carried out for detection of STAT1 and STAT1p levels in nuclear extracts (5 &#x3BC;g per sample). Heterogeneous nuclear ribonucleoprotein I (hnRNP I) was used as a loading control reference. <italic>b</italic>, STAT1 GAS DNA-binding capacity was evaluated by using EMSA. One microgram of nuclear extract was preincubated with 20,000 cpm of GAS probe at room temperature before nondenaturing PAGE separating free from STAT-bound probe.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
